Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|January 31, 2020
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast TumorsAna Alcaraz-Sanabria, Mariona Baliu-Piqué, Cristina Saiz-Ladera, et al.
Plos One|April 17, 2019
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumorsSara Morcillo-Garcia, Maria Del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, et al.
Theranostics|June 6, 2022
TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment responseTaewoo Kim, Jessica Johnston, Sonia Castillo-Lluva, et al.
Oncotarget|October 9, 2015
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesAlberto Ocana, Josee-Lyne Ethier, Laura Díez-González, et al.
Oncotarget|October 27, 2017
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 studyAlberto Ocana, Marta Gil-Martin, Miguel Martín, et al.
Oncoimmunology|October 25, 2019
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcomeMaría Del Mar Noblejas-López, Cristina Nieto-Jiménez, Sara Morcillo García, et al.
Frontiers in Immunology|January 11, 2020
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast TumorsJavier Pérez-Pena, Janos Tibor Fekete, Raquel Páez, et al.
British Journal of Pharmacology|May 5, 2025
Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti-PD1 resistance in skin cutaneous melanomaSzonja Anna Kovács, Tamás Kovács, András Lánczky, et al.
European Urology Oncology|July 7, 2019
Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysisIván A Rodríguez-Fernández, Laura Rodríguez-Romo, David Hernandez-Barajas, et al.
Clinical Epigenetics|July 9, 2026
Tumor-type specific methylation patterns of MTAP in human samples and cell linesLuis Álvarez-Carrión, Dalma Müller, Manuel Pedregal, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|January 31, 2020
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast TumorsAna Alcaraz-Sanabria, Mariona Baliu-Piqué, Cristina Saiz-Ladera, et al.
Plos One|April 17, 2019
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumorsSara Morcillo-Garcia, Maria Del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, et al.
Theranostics|June 6, 2022
TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment responseTaewoo Kim, Jessica Johnston, Sonia Castillo-Lluva, et al.
Oncotarget|October 9, 2015
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesAlberto Ocana, Josee-Lyne Ethier, Laura Díez-González, et al.
Oncotarget|October 27, 2017
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 studyAlberto Ocana, Marta Gil-Martin, Miguel Martín, et al.
Oncoimmunology|October 25, 2019
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcomeMaría Del Mar Noblejas-López, Cristina Nieto-Jiménez, Sara Morcillo García, et al.
Frontiers in Immunology|January 11, 2020
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast TumorsJavier Pérez-Pena, Janos Tibor Fekete, Raquel Páez, et al.
British Journal of Pharmacology|May 5, 2025
Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti-PD1 resistance in skin cutaneous melanomaSzonja Anna Kovács, Tamás Kovács, András Lánczky, et al.
European Urology Oncology|July 7, 2019
Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysisIván A Rodríguez-Fernández, Laura Rodríguez-Romo, David Hernandez-Barajas, et al.
Clinical Epigenetics|July 9, 2026
Tumor-type specific methylation patterns of MTAP in human samples and cell linesLuis Álvarez-Carrión, Dalma Müller, Manuel Pedregal, et al.
Pageof 10